Moderna, Inc. NMS · MRNA
Price alert —
Sign in to get a one-time email the moment MRNA crosses your price. Free accounts included.
Sign in / create a free accountModerna, Inc. is a biotechnology company best known for developing one of the leading COVID-19 vaccines using messenger RNA (mRNA) technology. The company's platform aims to develop vaccines and therapeutics across various disease areas, though its business has been closely tied to pandemic-related vaccine demand in recent years.
The stock recently closed at $61.82, down 2.11% for the day, placing it roughly in the middle of its 52-week trading range between $36.65 and $85.60. The technical picture shows MRNA is currently in a pullback phase, trading about 0.91 average true ranges below its 21-day moving average. The 2-period RSI reading of 6.9 is extremely low, suggesting the stock has experienced sharp selling pressure in the very near term.
Investors may want to watch whether Moderna can stabilize after this recent weakness, particularly as the company transitions beyond its COVID vaccine focus. The stock's position well above its 52-week low but significantly below its high reflects ongoing market uncertainty about the company's growth prospects in a post-pandemic environment.
A plain-English snapshot built from the data on this page — not investment advice. Always do your own research.
KC1 lower, -0.99 ATR from EMA21 — doji
- · KC1 lower stretch — light dip
- · Doji — indecision, watch for reversal
- · Aligned with strong uptrend (strong tailwind)
Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.
- · Doji — indecision, watch for reversal
- · Counter-trend short in strong uptrend
Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.
On the latest daily bar, momentum sits mid-range (RSI 46), the trend is strong (ADX 31), and trading is light at 0.5× normal volume. On the business side, revenue is growing 260% year over year and the business keeps about -1 cents of every sales dollar as free cash.
Latest-bar indicator readings behind the grade — display-only, they don't move the letter.
Company fundamentals for context — display-only, they don't move the grade.
The model's verdict is “Unknown” and accounting quality screens as Adequate. Model estimates only — do your own due diligence.
- ✓ More cash than debt
- ✓ Quick ratio 2.71 (antifragile)
- ✓ Current ratio 3.29 (antifragile)
- ✓ Debt/equity 0.43 (antifragile)
- ⚠ Inventory growing faster than revenue
- ⚠ Stock comp 25% of revenue (heavy dilution)
MRNA is a $24.5 billion company.
Options idea
See more →Earnings
See more →- Last reported
- 2026-04-30
- EPS (act / est)
- -1.18 / -3.96
- Surprise
- +70.2%
- Next report
- 2026-07-31
About
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; e…